Apogee Therapeutics Inc APGE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRBG, RMAX, GBCS, and APGE
-
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—AVB, APGE, TMHC, and LPRO
-
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—ACA, APGE, BOLD, and GBCS
-
Healthcare stocks have become a haven for investors ditching tech
-
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
-
AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion
-
APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
-
Correction to AbbVie to Buy Apogee Therapeutics Articles
Trading Information
- Previous Close Price
- $133.96
- Day Range
- $133.88–134.31
- 52-Week Range
- $34.34–134.31
- Bid/Ask
- $133.02 / $135.10
- Shares Outstanding
- 75.63M
- Market Cap
- $10.16B
- Volume/Avg
- 607,392 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 261
Valuation
|
Metric
|
APGE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.01 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APGE
|
|---|---|
Quick Ratio | 32.39 |
Current Ratio | 32.59 |
Interest Coverage | — |
Quick Ratio
APGE
Profitability
|
Metric
|
APGE
|
|---|---|
Return on Assets (Normalized) | −27.58% |
Return on Equity (Normalized) | −28.88% |
Return on Invested Capital (Normalized) | −31.52% |
Return on Assets
APGE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$QFpS? | LOCK|@qBh | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$#gB!Y | LOCK|xpQ%< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<d@xMD | LOCK|%M | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>mVFCY? | LOCK|>LYb | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|hh?dZM | LOCK|&L | $37B | |||
| Moderna Inc
MRNA
| LOCK|Dz?kWy | LOCK|d^r | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|t%@q#cB | LOCK|k@&d | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|<M^>K% | LOCK|<Wd | $23B | |||
| Incyte Corp
INCY
| LOCK|XcZ^%k? | LOCK|c? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<%tg>@ | LOCK|^$ | $16B |
United States